“German based biotech company CILIAN AG reports positive in vivo results for its seasonal sub-unit flu vaccine, CiFlu® . Immunogenicity studies were conducted in non-human primates. In collaboration with CILIAN’s scientific partners within the European ADITEC consortium, a quadrivalent seasonal flu vaccine was tested at the facilities of CEA’s Division of Immuno-Virology in Fontenay-aux-Roses, France. The tested vaccine contained recombinant hemagglutinin of two A-strains and two B-strains. Significant and strong immunogenicity measured with a standardized hemagglutination inhibition (HI) test was achieved and seroconversion occurred in the primates.”